Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer Read more about Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Agios Pharmaceuticals Reports First Quarter 2014 Financial Results Read more about Agios Pharmaceuticals Reports First Quarter 2014 Financial Results
Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2014 Financial Results on May 8, 2014 Read more about Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2014 Financial Results on May 8, 2014
Agios Pharmaceuticals Announces Pricing of Public Offering of Common Stock Read more about Agios Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Agios Pharmaceuticals Announces Proposed Offering of Common Stock Read more about Agios Pharmaceuticals Announces Proposed Offering of Common Stock
Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency Read more about Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers Read more about Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers
Agios Announces Clinical and Preclinical Data to be Presented at AACR Annual Meeting 2014 Read more about Agios Announces Clinical and Preclinical Data to be Presented at AACR Annual Meeting 2014
Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation Read more about Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation
Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation Read more about Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation